p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer

Abstract

The programmed death ligand 1 (PD-L1) is a pivotal biomarker of immunotherapy in triple negative breast cancer (TNBC). TP53 is reported as a positive regulatory predictor of immune efficacy. The correlation of p53 expression or mutation and PD-L1 expression is explored. By immunohistochemistry, PD-L1 expression between p53 mutation (missense and nonsense) and wild type; p53 no-expression/loss vs. expression were compared. There was a significant association between p53 mutation, especially missense mutation with higher histological grade, and PD-L1 expression in immune cells (ICs). Both p53 missense mutation and PD-L1 expression may be potential targets for improving immunotherapy response in TNBC.

Keywords:

• p53
• PD-L1
• triple-negative breast cancer
• TILs
• immunity therapy

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Data availability statement

All the data used to support the findings of this study are available from the corresponding author upon request.

Additional information

Funding

This work was supported by Natural Science Foundation of China [No. 81902884].